Healing Peptides: BPC-157, TB-500 and KPV Evidence (2026)

“Healing peptide” is the umbrella used for a handful of research compounds studied for tissue repair and inflammation — BPC-157, TB-500 and KPV are the three most searched. They get stacked together in the same recovery protocols, and on the two things that decide whether any of them is worth attention — the strength of the evidence and the legal status — they land closer together than the marketing suggests. Here is the sourced 2026 picture.

What are healing peptides?

The label covers peptides studied for wound, tendon, gut or soft-tissue repair. BPC-157 is a synthetic peptide studied for tendon, ligament and gut healing; TB-500 derives from thymosin β4 and is studied for wound and soft-tissue repair; KPV is the C-terminal tripeptide of α-MSH, studied for its anti-inflammatory action in inflammatory-bowel-disease and wound models. Same banner, related but distinct biology. The head-to-head comparisons are BPC-157 vs TB-500, BPC-157 vs KPV and TB-500 vs KPV.

BPC-157: the evidence

BPC-157 has the deepest preclinical base of the three — a large rodent corpus on tendon, gut and wound healing — and a thin layer of human data on top: a couple of small uncontrolled pilots and, as of 2026, one recruiting Phase 2 trial for acute hamstring strain. That makes it the only one of the three with any human trial at all, though a recruiting trial is not a result. The full indexed record is on the BPC-157 evidence and regulatory page, and for the legal angle specifically see is BPC-157 legal?.

TB-500: the evidence

TB-500, related to thymosin β4, is studied for soft-tissue and cardiac repair. Its record is preclinical, with one recruiting early-phase trial of a thymosin β4 fragment. No published randomized controlled trial. The indexed record is on the TB-500 evidence and regulatory page.

KPV: the evidence

KPV’s record is the thinnest of the three: cell and animal studies on inflammation, mostly in inflammatory-bowel-disease and colitis models, with no registered human trial. It is preclinical only. The indexed record is on the KPV evidence and regulatory page.

The honest state of the evidence

For how we sort a cell study from an animal study from a human trial, see how we grade peptide evidence. Applied to the healing peptides, BPC-157 grades highest but still short of proven; TB-500 and KPV are preclinical. Be careful with study counts: short or ambiguous names pull unrelated papers into a database tally, so a “human study” count is not human evidence for the molecule itself. The figure that matters — published human RCTs — is zero across all three.

Regulation: the July 2026 FDA vote

All three were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee reviews BPC-157, TB-500 and KPV on July 23, 2026. We break down the full agenda in the July 2026 FDA peptide meeting, explained. None carries a marketing authorization in the European Union, and as non-approved substances all three should be treated as prohibited under anti-doping rules.

The bottom line

Healing peptides are studied for real repair processes, but in 2026 none is a proven human therapeutic. BPC-157 is the most-researched and the only one with any human trial; TB-500 and KPV are preclinical. Start from the sourced comparisons above and watch the July 2026 vote for the next real change.

Research information only, not medical advice. None of these peptides is approved for human use. Talk to a licensed physician before considering any peptide.